• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

GRAS Notices

  • Print
  • Share
  • E-mail

GRN No. 1056

β-lactoglobulin produced by Komagataella phaffii strain yRMK-66

Intended Use: Intended for use as a source of protein at levels ranging from 5 to 35% in meal replacements and supplements, powdered nutritional beverages, electrolyte-type sport drinks, high protein performance nutritional beverages and bars, milk, milk drinks, yogurts, milk substitutes, creams and cream substitutes, cheeses, spreads and dips, milk-based desserts, mousses, confections, coatings and fillings, cookies, brownies, snack foods, baked goods, creamy salad dressings, minor main entrée sauces, and egg substitutes.
Basis: Scientific procedures
Notifier: Remilk Ltd.
Notifier Address: Holtzman 2
Rehovot, Israel 7670402
GRAS Notice (releasable information): GRN 1056 with Amendments (in PDF) (8.2 MB)
Date of closure: Feb 15, 2023
FDA's Letter: FDA Has No Questions (in PDF) (291 kB)